NAMS vs LNTH vs PRAX vs RMD vs MDT

For growth investors, ResMed Inc.

(RMD) is the stronger pick with 9. 8% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate NewAmsterdam Pharma Company N. V. (NAMS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

1x versus Lantheus Holdings, Inc. at 27. 5x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 05x versus Medtronic plc's 35. 17x — a reasonable growth-adjusted valuation.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +347. 0%, compared to -28. 5% for Medtronic plc (MDT). Over 10 years, the gap is even starker: LNTH returned +39. 8% versus PRAX's -17. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

39β versus Praxis Precision Medicines, Inc. 's 1. 51β — meaning PRAX is approximately 288% more volatile than MDT relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ResMed Inc.

(RMD) is pulling ahead at 9. 8% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: ResMed Inc. grew EPS 37. 4% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus -905. 7% for NewAmsterdam Pharma Company N. V. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -1002. 9% for NAMS. At the gross margin level — before operating expenses — NAMS leads at 99. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 05x versus Medtronic plc's 35. 17x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 18. 2x for ResMed Inc. — 4. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRAX: 60. 5% to $549. 80.

In this comparison, MDT (3.

7% yield), RMD (1. 0% yield) pay a dividend. NAMS, LNTH, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

39), 3. 7% yield). Praxis Precision Medicines, Inc. (PRAX) carries a higher beta of 1. 51 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +21. 9%, PRAX: -17. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NAMS is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; RMD is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock. RMD, MDT pay a dividend while NAMS, LNTH, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.